Background. Acute bacterial skin and skin-structure infections (ABSSSIs) are common causes of hospital admissions. These infections are often caused by methicillin-resistant Staphylococcus aureus; therefore, vancomycin remains a commonly used therapy. The purpose of this study was to compare hospital length of stay (LOS) in patients treated with vancomycin monotherapy vs combination therapy with clindamycin for ABSSSIs.
Acute bacterial skin and skin-structure infections (ABSSSIs) are among the most common infectious causes of hospital admissions. Gram-positive pathogens such as Staphylococcus aureus and Streptococcus spp. are largely responsible for the majority of ABSSSIs, with rates of hospitalization increasing substantially and rapidly [1] . From 1993 to 2005 there was an increase in annual emergency department (ED) visits for ABSSSIs from 1.2 million to 3.4 million [2] . Furthermore, it was determined that admissions for ABSSSIs increased by nearly 30%, while admissions for infections such as pneumonia remained stable, indicating that ABSSSIs are a critical rising health concern [3] . In a study of 11 EDs, it was estimated that 76% of all ABSSSIs were due to methicillin-resistant Staphylococcus aureus (MRSA) [4] . Considering that the majority of S. aureus isolates are methicillin resistant, it is recommended that patients with risk factors or with purulent ABSSSIs receive empirical therapy for MRSA [5, 6] .
Vancomycin remains the standard empirical therapy for MRSA infections globally [5, 7, 8] . Considering the increasing resistance rates of MRSA to vancomycin, the Infectious Diseases Society of America launched the 10 × '20 Initiative in order to encourage development of new antibiotics to treat a wide variety of antimicrobial-resistant infections including those caused by MRSA [9] . In 2014 alone, 3 agents (tedizolid, oritavancin, and dalbavancin) were approved for the treatment of MRSA ABSSSIs; however, they are costly alternatives and accordingly their role in therapy has yet to be determined [10] .
New antimicrobial agents are needed for these infections, but currently available agents can be utilized in ways not previously thought in order to successfully manage ABSSSIs, especially in the presence of an abscess. Abscesses complicate the treatment of ABSSSIs, with current guidelines recommending up to 14 days of antimicrobial therapy [6] . Appropriate incision and debridement (I&D) is the primary treatment for an abscess, but adjunctive antimicrobial therapy is also recommended in the presence of extensive disease, concomitant cellulitis, immunosuppression, extreme age, and/or incomplete drainage or lack of response to the debridement procedure [6] . It has been hypothesized that antibiotics provide incremental benefit over drainage alone for cutaneous abscesses, which may be due to a lesser-known phenomenon, that is, the Eagle, or inoculum, effect [1, 11] .
The Eagle effect was first observed in 1954 when Dr Harry Eagle described the limitations of penicillins in toxin-mediated streptococcal infections with high stagnant bacterial concentrations [11] . He observed that infections with a large amount of bacteria (such as an abscess) are in a stationary-growth phase. As these organisms are not actively dividing, beta-lactam and glycopeptide antibiotics are rendered relatively ineffective. However, the incorporation of antibiotics that disrupt protein synthesis may improve abscess penetration, cease toxin production, and cause the bacteria to begin actively replicating [12] [13] [14] . Therefore, this alteration of protein synthesis may increase the efficacy of previously ineffective beta-lactam or glycopeptide antibiotics when utilized as combination therapy [12] [13] [14] .
This study was designed to examine the effect of synergy between the glycopeptide vancomycin and the lincosamide protein synthesis inhibitor clindamycin on clinical outcomes. The primary purpose of this study was to compare the mean hospital length of stay (LOS) in patients with ABSSSIs that were treated with vancomycin and clindamycin combination therapy vs vancomycin monotherapy.
METHODS
This was an institutional review board-approved, retrospective review of patients admitted to a 941-bed tertiary, regional referral hospital in northern Alabama between January 2010 and December 2013 with diagnostic-related group numbers related to ABSSSIs. Patients were included if they were diagnosed with an ABSSSI, aged ≥19 years, and received either vancomycin monotherapy or vancomycin in combination with clindamycin for a minimum of 48 hours from the onset of IV antibiotic therapy. Patients could receive antibiotics in addition to the study antibiotics if those agents did not have activity against MRSA and MRSA was ultimately cultured. Patients were excluded from the study if they did not meet the above criteria, had a diagnosis other than ABSSSI such as diabetic foot infection, osteomyelitis, septic arthritis, or necrotizing fasciitis, or if antibiotic therapy changed during the course of hospitalization, such that the study antibiotics were no longer administered.
The primary outcome of the study was hospital LOS. The secondary outcome was any infection-related 90-day hospital readmission as determined by admission diagnosis and confirmed by discharge summary. With respect to those outcomes, variables such as outpatient antibiotic prescriptions given prior to admission, MRSA cultures, status of I&D of an abscess, and comorbid diabetes were also examined to determine impact on LOS or 90-day readmission. Other variables examined included discharge antibiotics, susceptibility patterns of MRSA, incidence of acute kidney injury (AKI), and rates of Clostridium difficile-associated diarrhea (CDAD). Discharge antibiotics were determined by prescribers' discharge instructions and hospital discharge medication record form. For patients with infections caused by MRSA, the minimum inhibitory concentration (MIC) was determined using MicroScan PROMPT (3 M Company, St. Paul, Minnesota). Reports of the MIC were given as <1 mg/L, 1 mg/L, and 2 mg/L. When the MIC was 2 mg/L, the result was confirmed using MicroScan turbidity testing (Siemens, Inc., Malvern, Pennsylvania). AKI was defined as an increase in serum creatinine (Cr S ) by at least 1.5 times baseline, and CDAD was defined as the detection of C. difficile via polymerase chain reaction in symptomatic patients [15] .
A sample of 267 patients was needed in order to provide 90% power with a 2-sided alpha of 0.05. All parametric data were initially analyzed using Student t test. All categorical variables and proportions were analyzed using χ 2 test. Upon determination of statistical significance, a general linear model with a Poisson log link was used to compare monotherapy and combination therapy on LOS as has been suggested previously [16] . Due to a small sample size, we used a backward stepwise selection (entry and stay = 0.1) process to evaluate treatment, I&D status, diabetes, outpatient antibiotics, and corticosteroid therapy. For the secondary outcome of 90-day readmission, once statistical significance was determined, a manual logistic regression was conducted to determine variables that may have impacted readmission including combination therapy, I&D status, diabetes, and outpatient antibiotics received prior to admission. Not all patients had positive culture data; therefore, those with positive MRSA cultures were analyzed in a separate analysis using χ 2 test to determine differences in demographics in those patients. In this population, backward stepwise selection (entry and stay = 0.1) linear regression using the variables of treatment, diabetes, abscess, and I & D status was completed to assess impact on hospital LOS. Manual logistic regression using the same variables was done to assess impact on 90-day readmissions. Fisher exact test was used to determine differences in adverse effect outcomes between the 2 groups. All statistical analyses were performed using SPSS software, version 22 (IBM Corporation).
RESULTS
A total of 594 patients with ABSSSIs were screened, 269 of whom met criteria for inclusion in this study. Reasons for exclusion are listed in Supplementary Appendix A. Demographics were similar between the groups, with the exceptions that patients in the monotherapy group were approximately 5 years older than those in the combination group, had a higher percentage of diabetes, and had a higher percentage of MRSA infections (Table 1) . Significantly more patients in the combination group received I&D.
Primary Outcome
Among the entire study population, a decrease in LOS (Table 2) was not statistically significantly associated with combination therapy (3.7 ± 1.4 days vs 4.0 ± 2.0 days; 95% confidence interval Table 3 ).
Secondary Outcomes

90-Day Hospital Readmission
In the entire study population, 23 patients (9%) were readmitted for infection-related causes within 90 days of discharge. A significantly lower rate of readmission was observed in patients who received combination therapy with vancomycin and clindamycin compared with those who received vancomycin monotherapy for the entire cohort, as well as for the subgroup with abscesses (Table 4 ). Manual logistic regression was conducted to determine if presence of diabetes, I&D, and antibiotic therapy prior to admission also contributed to the lower rate of readmissions in both patients with abscesses and all ABSSSIs (Table 4 ). In the entire population, only treatment with combination therapy was found to be associated with fewer readmissions. Patients receiving combination therapy were 69% less likely to be readmitted than patients receiving monotherapy (P = .009).
In the subgroup of patients with abscesses, both combination therapy and I&D were found to decrease 90-day readmission rates (Table 5) . Of the 9 patients who were readmitted with abscesses, 7 received monotherapy whereas only 2 received combination therapy. Approximately half of the patients in each group received I&D; 4 monotherapy patients and 1 combination therapy patient, for a total of 5 patients receiving I&D vs 4 patients who did not receive I&D in the total subgroup population. Patients with abscesses treated with combination therapy were 88.5% less likely to be readmitted than patients receiving monotherapy (P = .011). Patients who had I&D were 86% less likely to be readmitted than patients without I&D (P = .017).
Methicillin-Resistant Staphylococcus aureus
A total of 146 patients (54%) had positive infection-site cultures. The most common organism isolated was MRSA, which was responsible for 102 (70%) of the ABSSSIs in the study population, with 64 in the combination group and 38 in the monotherapy group. The majority of patients with MRSA infections had abscesses, 53 (82%) in the combination group and 29 (76%) in the monotherapy group (P = .638). Six MRSA isolates had an MIC of 2 mg/L, 2 (3%) in the combination group and 4 (10.5%) in the monotherapy group (P = .192). Risk factors for hospital-acquired MRSA were evaluated in those infected with MRSA, including nursing home residency, healthcare occupation, previous admission in the past 90 days, history of MRSA skin infections, intravenous drug abuse, and immunocompromised state. Patients were considered in an immunocompromised state if they received treatment with any immunosuppressive medication (eg, monoclonal antibody, chemotherapy, corticosteroids) or if they had diabetes, cancer, end-stage renal disease, or any disorder of the immune system. There was no difference between treatment groups with respect to percentages of patients with or without risk factors (Figure 1 ). In the subgroup of patients who cultured MRSA, 90-day readmission was significantly lower in the combination group, 1 patient vs 8 patients (P = .0014). Linear regression demonstrated no association between treatment with combination therapy and decreased LOS in this subgroup (3.73 ± 1.46 vs 4.37 ± 2.33; P = .09). Logistic regression determined that only treatment with combination therapy was associated with decreased 90-day readmission rates (Table 6 ).
Discharge Antibiotics
Patients in the study were discharged on a wide variety of antibiotics ( Figure 2 ). Both treatment groups were most commonly discharged on sulfamethoxazole-trimethoprim (42% in the combination group, 38% in the monotherapy group). More patients in the combination group were discharged on clindamycin (39% vs 15.5%; P = .0001). In contrast, more patients in the monotherapy group were discharged on vancomycin (11% vs 3%; P = .006), linezolid (6% vs 0.5%; P = .003), or daptomycin (2.5% vs. 0%; P = .025). Patients in the combination group were discharged with a significantly shorter duration of antibiotics than those in the monotherapy group (8.6 ± 2.8 days vs. 10.2 ± 3.73 days; P = .0001).
Safety: Acute Kidney Injury and Clostridium difficile-Associated Diarrhea
Five (1.85%) patients in the entire study population experienced Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease class "risk" of AKI, all of which occurred in the combination group. However, this difference was not significantly different between groups (P = .329). When evaluating the risk factors associated with vancomycin-associated nephrotoxicity (VAN), it was discovered that 1 patient with chronic kidney disease receiving furosemide, indomethacin, and lisinopril experienced an increase in Cr S from 1.3 mg/dL to 2.0 mg/dL. Another patient receiving concomitant furosemide therapy had an increase in Cr S from 0.7 mg/dL to 1.2 mg/dL. A third patient on concomitant cimetidine received a vancomycin dose of 20 mg/kg, yielding a trough level of 38 mg/L, and experienced an increase in Cr S from 0.5 mg/dL to 1.1 mg/dL. The final 2 cases of VAN could not be explained, as no risk factors were present. One patient had an increase in Cr S from 0.3 mg/dL to 1.0 mg/dL (it was unclear whether the initial 0.3 mg/dL was accurate as all other Cr S levels ranged from 0.8 to 1.0 mg/dL), and the other had an increase in Cr S from 0.8 mg/dL to 1.4 mg/dL. The average daily vancomycin dose among the entire population was 2389.6 ± 856.7 mg, correlating to an average of 14.9 ± 3.4 mg/kg/dose. A total of 82 patients (30%) had vancomycin trough levels drawn, with an average level of 10.5 ± 6.5 mg/L (range, 3-41 mg/L). No cases of CDAD occurred in patients while receiving treatment or in the 90-day follow-up for either group.
DISCUSSION
ABSSSIs have become a common cause for hospital admissions, and MRSA is the causative pathogen for the majority of these admissions [1] . Although newer agents are available to treat these infections, they have significantly higher acquisition costs compared with vancomycin. We conducted this retrospective study to compare the effectiveness of 2 older antimicrobials in an effort to determine if the combination of vancomycin and clindamycin decreased LOS and 90-day readmission rates compared with vancomycin alone. This study demonstrated an association between treatment with a combination of vancomycin and clindamycin and decreased LOS for patients with abscesses, as well as decreased hospital readmissions in 90 days. This study is not without limitations and warrants further investigation through a randomized, prospective study to compare the 2 treatment options. Due to the retrospective nature of the study, we relied on information gathered from patients' medical records. As such, not all information was available. For example, we were unable to assess the actual size of the skin infections and abscesses and were unable to assess the success of I&D. These factors could have played a role in how quickly the infection resolved and, consequently, hospital LOS.
Another limitation was that we were unable to capture information about patients who were readmitted to other institutions or who sought care outside of our hospital system. This could have impacted the association we observed in decreased 90-day readmissions with the combination therapy compared with monotherapy. In addition, the relative safety of combination therapy could be overestimated, as patients who developed CDAD may have sought care at another institution.
In an effort to keep a relative 2:1 ratio of combination therapy to monotherapy, certain factors could not be controlled for in the baseline demographics. There was a difference between the groups in age, where the monotherapy group was approximately 5 years older than those in the combination therapy group. We assessed the correlation between LOS and age since we could not control for this discrepancy and discovered a weak association (correlation coefficient = 0.237). We also could not control for the presence of concomitant diabetes or other immunocompromised states in the population. One could argue that patients with diabetes and those who are immunocompromised would have a longer course of illness and thus a longer LOS and greater potential for readmission. However, upon conducting linear regression, Poisson log link, and logistic regression analyses, it was determined that these factors did not impact LOS or 90-day hospital readmissions. Furthermore, these analyses showed that infections caused by MRSA were not associated with increased LOS or 90-day hospital readmissions compared with infections caused by other pathogens. On the contrary, we found that while patients with MRSA treated with combination therapy had no association with a decreased LOS, there was an association with fewer 90-day hospital readmissions compared with treatment with vancomycin monotherapy.
Infections caused by MRSA occurred in 102 patients in the population studied. There was no difference between the 2 treatment arms in the percentage of patients with risk factors for MRSA. Patients with 1 or fewer risk factors were more commonly observed than those having more than 1 risk factor. The most common risk factors demonstrated were previous MRSA skin infections and immunocompromised conditions. In addition, we exhibited an overall low percentage of MRSA isolates with an MIC of 2 mg/L (6%). In those patients, the LOS was found to be significantly longer than in those with an MRSA MIC <2 mg/L. Although these findings are based upon 6 vs 96 isolates, it is certainly worth exploring this association in future studies.
A final limitation of this study was that a cost-effectiveness analysis was not conducted. While it can be assumed that a decrease in LOS would decrease overall costs, this outcome was not evaluated. Future studies should examine this and compare the combination to newer agents such as daptomycin, linezolid, tedizolid, ceftaroline, and the glycopeptides dalbavancin, telavancin, and oritavancin.
CONCLUSIONS
Monotherapy with vancomycin along with I&D has been the standard management of ABSSSIs for many years. However, our study showed that the combination of vancomycin and clindamycin is an effective and possibly better alternative than vancomycin monotherapy for the treatment of ABSSSIs. The results of this study demonstrated that the combination of vancomycin Figure 2 . Antibiotics prescriptions with which patients were discharged from the hospital (*P < .05). and clindamycin was associated with a decreased LOS in patients with abscesses and fewer readmissions in 90-days for all ABSSSIs. This treatment option should be explored further through a larger, prospective study in order to validate these results.
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